Annual Congress Munich 2006

Saturday, 02.09.2006
Sunday, 03.09.2006
Monday, 04.09.2006
Tuesday, 05.09.2006
Wednesday, 06.09.2006

Citations should be made in the following way: Authors. Title. Eur Respir J 2006; 28: Suppl. 50, abstract number.

Material from 2006:

4395 Abstracts
610 Slide presentations
175 Webcasts
95 Handouts
175 Multimedia files

Material from 2006: Show

Recent advances in the treatment of COPD

Oral Presentation
Chairs: M. Cazzola (Naples, Italy), K. F. Rabe (Leiden, The Netherlands)

Download all media

Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD R. A. McIvor, L. M. Fabbri, F. Sanchez-Toril, S. Silberborth, A. Rempel, C. Gartner, D. Bredenbroeker, P. M. Calverley (Halifax, Canada; Modena, Italy; Valencia, Spain; Konstanz, Germany; Liverpool, United Kingdom)
Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial M. Decramer, B. Celli, D. P. Tashkin, D. Burkhart, S. Kesten, C. Cassino (Leuven, Belgium; Boston, Los Angeles, Ridgefield, United States Of America)
Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease N. A. Molfino, S. Mallikaarjun, P. Zhang, S. Shoaf, K. Mitsui (Rockville, United States Of America)
Effects of long-acting inhaled β-adrenergic and anticholinergic drugs on respiratory function and arterial blood gases in patients with COPD M. Cazzola, N. Morelli, S. Pizzolato, P. Buratto, E. Belloli, S. Centanni (Naples, Milan, Italy)
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease K. A. Gunawardena, R. N. Wild, J. Kirkpatrick, S. D. Snape (Slough, Huntingdon, Cambridge, United Kingdom)
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD D. Singh, P. A. Corris, R. Tansley (Manchester, Newcastle, Cambridge, United Kingdom)
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) R. A. Wise, M. R. Littner, P. Zhang, S. Mallikaarjun, K. Mitsui, C. Orlandi, N. A. Molfino (Baltimore, Sepulveda, Rockville, United States Of America)
Indacaterol, a novel once-daily β₂-agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD S. Rennard, T. Bantje, M. Higgins, D. Jack, R. Owen (Omaha, United States Of America; Breda, Netherlands; Horsham, United Kingdom)